89 related articles for article (PubMed ID: 9198162)
1. Second generation, B-domain deleted recombinant factor VIII.
Berntorp E
Thromb Haemost; 1997 Jul; 78(1):256-60. PubMed ID: 9198162
[TBL] [Abstract][Full Text] [Related]
2. Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients.
Fijnvandraat K; Berntorp E; ten Cate JW; Johnsson H; Peters M; Savidge G; Tengborn L; Spira J; Stahl C
Thromb Haemost; 1997 Feb; 77(2):298-302. PubMed ID: 9157585
[TBL] [Abstract][Full Text] [Related]
3. [Factor VIII preparation produced by recombinant DNA-technology is approved in Norway].
Briseid G; Arntzen FC
Tidsskr Nor Laegeforen; 1995 Jun; 115(15):1849-51. PubMed ID: 7638835
[TBL] [Abstract][Full Text] [Related]
4. Hemophilia treatment. Factor VIII inhibitors with recombinant products: prospective clinical trials.
Lusher JM
Haematologica; 2000 Oct; 85(10 Suppl):2-5; discussion 5-6. PubMed ID: 11187864
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy, safety and pharmacokinetic properties of the factor VIII concentrate Haemoctin SDH in previously treated patients with severe haemophilia A.
Wolf DM; Rokicka-Milewska R; Lopaciuk S; Skotnicki AB; Klukowska A; Laguna P; Windyga J; Kotitschke R; Struff WG
Haemophilia; 2004 Sep; 10(5):438-48. PubMed ID: 15357768
[TBL] [Abstract][Full Text] [Related]
6. Structural and functional characteristics of the B-domain-deleted recombinant factor VIII protein, r-VIII SQ.
Sandberg H; Almstedt A; Brandt J; Gray E; Holmquist L; Oswaldsson U; Sebring S; Mikaelsson M
Thromb Haemost; 2001 Jan; 85(1):93-100. PubMed ID: 11204595
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up.
Mauser-Bunschoten EP; Posthouwer D; Fischer K; van den Berg HM
Haemophilia; 2007 Nov; 13(6):697-700. PubMed ID: 17877729
[TBL] [Abstract][Full Text] [Related]
8. [Production of factor VIII by genetic techniques].
Neutzling O
Beitr Infusionsther; 1993; 31():38-43. PubMed ID: 7693262
[TBL] [Abstract][Full Text] [Related]
9. [New approaches to haemophilia treatment--recombinant and transgenic concentrates, gene therapy and engineered coagulation factors].
Habart D
Cas Lek Cesk; 2006; 145(2):104-11. PubMed ID: 16521398
[TBL] [Abstract][Full Text] [Related]
10. Pasteurized, monoclonal antibody factor VIII concentrate: establishing a new standard for purity and viral safety of plasma-derived concentrates.
Goldsmith JC
Blood Coagul Fibrinolysis; 2000 Mar; 11(2):203-15. PubMed ID: 10759015
[TBL] [Abstract][Full Text] [Related]
11. Structure and function of the factor VIII gene and protein.
Thompson AR
Semin Thromb Hemost; 2003 Feb; 29(1):11-22. PubMed ID: 12640560
[TBL] [Abstract][Full Text] [Related]
12. Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.
Berntorp E; Windyga J;
Haemophilia; 2009 Jan; 15(1):122-30. PubMed ID: 19149848
[TBL] [Abstract][Full Text] [Related]
13. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.
Auerswald G; Spranger T; Brackmann HH
Haematologica; 2003 Jun; 88(6):EREP05. PubMed ID: 12826531
[TBL] [Abstract][Full Text] [Related]
14. A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose.
Rubinger M; Lillicrap D; Rivard GE; Teitel J; Carcao M; Hensman C; Walker I;
Haemophilia; 2008 Mar; 14(2):281-6. PubMed ID: 18194308
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of coagulation equilibrium at baseline and during factor VIII and factor IX replacement in haemophiliacs.
Négrier C; Menart C; Attali O; Petit PY; Lienhart A; Dechavanne M; Ingerslev J
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S135-41. PubMed ID: 9819045
[TBL] [Abstract][Full Text] [Related]
16. Hemophilia. Strategies for the treatment of inhibitor patients.
Ingerslev J
Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
[TBL] [Abstract][Full Text] [Related]
17. Pasteurization as an efficient method to inactivate blood borne viruses in factor VIII concentrates.
Hilfenhaus J; Weidmann E
Arzneimittelforschung; 1986 Apr; 36(4):621-5. PubMed ID: 3013213
[TBL] [Abstract][Full Text] [Related]
18. Recombinant factor IX.
White GC; Beebe A; Nielsen B
Thromb Haemost; 1997 Jul; 78(1):261-5. PubMed ID: 9198163
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort.
Gaboulaud V; Parquet A; Tahiri C; Claeyssens S; Potard V; Faradji A; Peynet J; Costagliola D;
Br J Haematol; 2002 Feb; 116(2):383-9. PubMed ID: 11841442
[TBL] [Abstract][Full Text] [Related]
20. A retrospective survey on the safety of Replenate, a high-purity factor VIII concentrate.
Gascoigne EW; Dash CH; Harman C; Wilmot D
Pharmacoepidemiol Drug Saf; 2004 Apr; 13(4):243-52. PubMed ID: 15255091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
